Co-expression of BubR1 and UCHL1 in salivary gland tumors

Abstract

Objective: Salivary gland tumors (SGTs) are one of the most heterogeneous and challenging neoplasms affects human. Several biomarkers have been used to study proliferation, angiogenesis, prognosis, metastasis and recurrence of SGTs. The aim of this study was to evaluate, compare and correlate the co-expression of Budding Uninhibited by Benz imidazole Related 1 (BubR1) and Ubiquitin C-terminal hydrolase-L1 (UCHL1) immunomarkers in SGTs. 
 Methods: The immunohistochemical expression of BubR1 and UCHL1 were performed with formalin fixed paraffin embedded tissue sections of 35 retrieved blokes of SGTs. The expression, pattern of reactivity, intensity and subcellular localization of these markers are studied. T-test was used to find statistical difference in expression immunomarkers.
 Results: All of the cases were positive for both BubR1 and UCHL1. The intensity of reaction differed between the tumor types. A significant difference was seen in the expression of BubR1 in benign versus malignant tumors (P=.002) and pleomorphic adenoma versus mucoepidermoid carcinoma (P=.001). While statistically significant difference was not seen in the expression of UCHL1 between the tumors mentioned above (P=.81 and P=.83, respectively). Finally, there was a significant difference between the expressions of BubR1 and UCHL1 in SGTs (P=.001), indicating a higher expression of UCHL1 in SGTs. 
 Conclusions: UCHL1 has a higher percentage and intensity of reactivity in SGTs as compared to BubR1, While BubR1 is a better immunomarker for distinguishing between benign and malignant tumors.